



School of Continuous
Professional Development



Innovative Data Strategies

Tried and True & New and Promising

Rickey Carter, PhD
Department of Quantitative Research
Mayo Clinic

Disclosure

- No relevant disclosures

Objective


- Describe how implementing pragmatic elements to the study design may increase generalizability of the findings

Clinical Trials as a Spectrum


- No single trial provides “definitive” evidence
 - Rather, it’s the compilation of knowledge
- What is “Real World”?

Clinical Trials as a Spectrum

Traditional Clinical Trial Phases



Pragmatic Clinical Trials



PRECIS-2, BMJ publication BMJ 2015;350:h2147

Pilot Studies

Pilot Studies

Recommendations for Planning Pilot Studies in Clinical and Translational Research

Charity G. Moore, Ph.D.¹, Rickey E. Carter, Ph.D.², Paul J. Nietert³, and Paul W. Stewart, Ph.D.⁴

Abstract

Advances in clinical and translation science are facilitated by building on prior knowledge gained through experience. In the context of drug development, preclinical studies are followed by a progression of phase I through phase II. The study design and statistical strategies are framed around research questions that are prerequisites for the biomedical research, pilot studies are used for gathering preliminary support for the next research step. However, pilot studies are often liberally applied to projects with little or no funding, characteristic of studies with poorly developed research proposals with no detailed thought of the subsequent study. In this article, we present a rigorous definition of a pilot study, the design, analysis and sample size justification of pilot studies in clinical and translational research, and empirical evidence that well-designed pilot studies play in the advancement of science and scientific careers. Clin Trans Sci 2011; Vol 1; No 1; pp 1-10

Keywords: pilot studies, pilot study design, sample size, power calculations, confidence intervals

Clinical and Translational Science

<https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/j.1752-8062.2011.00347.x>




Figure 1. Nonproductive scientific strategy involving the use of pilot studies.

4 Strategies to Improve Pilot Studies

1. Keep the next study in mind

- What is it that we really need to learn with this study?
- Do we know if patients will accept randomization?
- Can we supply and administer the investigational product in time?
- Can we generate preliminary data to support further study?

4 Strategies to Improve Pilot Studies

2. Design with carefully specified aims

- (False) Aim – To conduct an under-powered, under-resourced clinical trial that will produce challenging to interpret data that will only result in a pay-for-publication article in an obscure open-access medical journal for a bargain price of \$4,500.
- (Pilot) Aim – To quantify the rate of accrual by ascertaining the percentage of eligible patients that are successfully randomized into the clinical trial.

4 Strategies to Improve Pilot Studies

3. Justify the Sample Size

- All studies require adequate sample size justification
- This is an “art”; no single right answer
- There are wrong answers -
 - We think the clinically relevant difference is a reduction in mortality of 3 percentage points (RR = 0.9). However, our budget is limited so we will let the sample size calculations be based on a 25 percentage point difference (RR= 0.001) because that is all the subjects the budget allows.

4 Strategies to Improve Pilot Studies

4. Career Trajectories Matter

- Well designed pilot studies are quick to run
- Defined questions convincingly answered are publishable

Pilot Studies for Pragmatic Clinical Trials

- Assess logistics
 - Randomization workflow, particularly if individual patient randomization
 - Establish data collection procedures (i.e., EHR integration, electronic vs. “paper” collection)
 - Evaluate protocol compliance
 - Evaluate patient flow:
 - Patients => Screening Rate => Randomization Rate

Go / No Go Decisions

- Based on the believed study viability and funding
- “Gut check” – Is this really what you want to do for the next 3 – 7 years?
- Do you have the team assembled and ready?
- Could it be done? vs. Should it be done?

Case Study – Mayo Expert Advisor Study

CLINICAL RESEARCH STUDY

THE AMERICAN
JOURNAL of
MEDICINE®

Computerized Advisory Decision Support for Cardiovascular Diseases in Primary Care: A Cluster Randomized Trial



Paul M. McKie, MD, MPH,^a Daryl J. Kor, MD,^{b,c} David A. Cook, MD, MHPE,^{d,e} Maya E. Kessler, MD, MPH,^f
Rickey E. Carter, PhD,^{b,g} Patrick M. Wilson, MPH,^g Laurie J. Pencille, CCRP,^{b,d} Branden C. Hickey, BS, MAS,^d
Rajeev Chaudhry, MBBS, MPH^{d,f}

^aDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn; ^bRobert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn; ^cDepartment of Anesthesiology, Mayo Clinic, Rochester, Minn; ^dOffice of Information and Knowledge Management, Mayo Clinic, Rochester, Minn; ^eDivision of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minn; ^fDivision of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minn; ^gDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minn.

CLINICAL SIGNIFICANCE

- The studied clinical decision support tool improved adherence to guideline-recommended therapy for heart failure but not atrial fibrillation or hyperlipidemia.
- Complex diseases may respond more favorably to decision support tools.
- The limited use of decision support tools in a real-world clinical practice highlights the need to address barriers to usage before widespread implementation.



<https://doi.org/10.1016/j.amjmed.2019.10.039>

Clinical Decision Support Tool

https://ars.els-cdn.com/content/image/1-s2.0-S0002934319310836-gr4_lrg.jpg

MayoExpertAdvisor Patient-specific care recommendations and knowledge resources.

Patient, Test **Conditions** ⓘ

B Blood Pressure
145/85 mm/Hg 08-Aug-2016

Heart Rate
58.0 bpm 08-Aug-2016

Weight
95.0 kg 08-Aug-2016

BMI
38.1 08-Aug-2016

Primary Physician
Provider, Test

Refresh data

Feedback
Please help improve this product by [providing feedback](#).

Hyperlipidemia

→ Care Recommendation:
Consider moderate- to high-intensity statin therapy due to LDL ≥190 **A**

C **Relevant Patient Data**

Demographics
Adult

Conditions/Problems
Hyperlipidemia

Lab Results

Total cholesterol	289 mg/dL	13-Nov-2014
HDL	73 mg/dL	13-Nov-2014
LDL	200 mg/dL	13-Nov-2014
Non HDL Cholesterol	217 mg/dL	13-Nov-2014

D **Resources for Next Steps**

- Moderate- to high-intensity statin dosing and surveillance recommendations
- 10 Year Risk of Major Cardiac Event (ACC ASCVD): 3.4% **E** [View tool](#)
- 30 Year Risk of Major Cardiac Event: 25% [View tool](#)

F **Decision Aids**
** Statin Decision Aid **

Ask Mayo Expert
Hyperlipidemia

G **Patient Education**
Hyperlipidemia

[Hide details and knowledge resources](#) ^

A. Care Recommendation

Depending on the individual patient's date in the EHR, MEA makes a recommendation.

B. Vitals

Most recent outpatient vital signs.

C. Relevant Patient Data

The most relevant demographics, conditions, and labresults for managing the given condition.

D. Resources for Next Steps

Additional condition-specific tools (e.g. list of moderate and high intensity statins) to assist in recommendations.

E. Risk Calculators

Condition-specific risk calculators with a patient's data prefilled for real-time calculations.

F. Decision Aids


Mayo-vetted shared decision-making tools. Field values are prefilled with patient data.

CDS Goal:

- Extract relevant history
- Cross reference with guidelines and best practice
- Provide actionable recommendation

Recipe
for Success?

Actionable Encounters in Primary Care Setting



[Download : Download high-res image \(597KB\)](#)


[Download : Download full-size image](#)

Relevant Pilot Questions

- What are the reasons for the primary care visits?
- Is chronic disease management actionable during these visits?
- “We will discuss at our next visit”

Figure 1. Patient visits with a discrepancy between previsit treatment and guideline-recommended treatment for heart failure, hyperlipidemia, and atrial fibrillation.

PRECIS Applied to Mayo Expert Advisor Study



Eligibility – 5 (Usual Care)

Recruitment – 5 (Cluster rand.)

Setting – 3 (MC Primary Care)

Organization – 2 (IT heavy)

Delivery – 4 (Just an extra "click")

Adherence – 5 (Ignorable)

Follow up – 4 (Mayo Care)

Outcome – 1 (Not patient focused)


Analysis – 1 (Heavy subsetting)

Where did all of the patients go? (“Lasagna’s Law”)

Incident Cases



Prevalent Cases



“We see these patients all the time”



Randomized Cases

Where did all of the patients go? (“Lasagna’s Law”)




Month 1



Months 1+

Randomization
is based on
incident cases

Pandemic Example Convalescent Plasma Trial Enrollment




Emphasizes need
for adaptive
enrollment strategies

The “global”
pandemic required
local attention

Opportunities for the Future

- Ready and waiting site network
 - Rapid activation/deactivation
- “Warm” infrastructure beneficial
- Focus on diversity
 - Rural vs. Urban, Academic vs Community, Private vs. Government Insurance



2,722

Total Sites Registered

12,889

Total Physicians Registered

105,717

Total Patients Consented

94,287

Total Patients Transfused



THANK YOU

CARTER.RICKEY@MAYO.EDU



@RICKEY_CARTER